The U.S. Blood Transfusion Diagnostics Market plays an important role in supporting the safety and effectiveness of blood transfusion procedures. Blood transfusion diagnostics include testing solutions used to screen blood, identify blood groups, detect infectious diseases, and assess compatibility between donors and recipients. These diagnostic procedures are essential for reducing transfusion-related risks and maintaining the quality of blood supplies.
According to Fortune Business Insights, the U.S. blood transfusion diagnostics market size was valued at USD 1.91 billion in 2021. The market is projected to grow from USD 2.20 billion in 2022 to USD 3.58 billion by 2029, exhibiting a CAGR of 7.2% during the forecast period. The broader global market experienced a 6.5% decline in 2020 compared with 2019, reflecting the effects of the COVID-19 pandemic. During the pandemic, blood transfusion diagnostics experienced lower-than-anticipated demand in the U.S. compared with pre-pandemic levels.
The rising number of surgical procedures, trauma cases, chronic disease treatments, and other medical interventions requiring blood components is supporting demand for transfusion diagnostics in the U.S. Hospitals and blood banks depend on accurate diagnostic testing to ensure that blood products are suitable for transfusion.
Testing helps identify blood groups and potential incompatibilities before transfusion. It also supports screening processes designed to identify infections and other conditions that could compromise the safety of donated blood.
Blood safety remains an important consideration for healthcare providers and blood collection organizations. Diagnostic testing allows blood centers to evaluate donated blood before it enters the transfusion supply chain.
Advancements in screening technologies have improved the ability of laboratories to detect infectious agents and other potential risks. The continued emphasis on stringent blood screening practices is expected to support the development of the U.S. Blood Transfusion Diagnostics Market.
For detailed market insights : https://www.fortunebusinessinsights.com/u-s-blood-transfusion-diagnostics-market-107024
The market includes diagnostic products and solutions used across different stages of the blood transfusion process. These include blood grouping and typing systems, infectious disease screening tests, compatibility testing solutions, reagents, instruments, and related diagnostic technologies.
Automated testing systems are increasingly important because they can process larger numbers of samples while reducing manual procedures. Automation can also support standardized workflows in blood banks and clinical laboratories.
Based on technology, the U.S. Blood Transfusion Diagnostics Market incorporates methods such as molecular diagnostics, immunoassays, and other diagnostic technologies.
Molecular diagnostic techniques can provide sensitive detection of infectious agents, while immunoassay-based approaches are widely used for screening and identifying specific biological markers. Continued technological development is supporting the availability of faster and more efficient diagnostic solutions.
Automation and digital laboratory systems are also becoming increasingly relevant as healthcare facilities seek to improve testing workflows and manage growing diagnostic volumes.
Key end users include hospitals, blood banks, diagnostic laboratories, and other healthcare institutions.
Blood banks represent an important end-user group because they perform extensive donor screening, blood typing, and testing before blood components are distributed. Hospitals also require transfusion diagnostics to evaluate compatibility and support patient safety during transfusion procedures.
Diagnostic laboratories contribute to the market by providing specialized testing capabilities and processing samples for healthcare facilities that may not maintain comprehensive in-house diagnostic infrastructure.